Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Current Psychiatry Reports
Erschienen in: Current Psychiatry Reports 4/2012

01.08.2012 | Eating Disorders (E Attia, Section Editor)

Antipsychotic Agents in the Treatment of Anorexia Nervosa: Neuropsychopharmacologic Rationale and Evidence from Controlled Trials

verfasst von: Timothy D. Brewerton

Erschienen in: Current Psychiatry Reports | Ausgabe 4/2012

Einloggen, um Zugang zu erhalten

Abstract

The search for an effective psychopharmacologic strategy in the treatment of anorexia nervosa (AN) has been elusive for decades and has run the gamut from reserpine to typical antipsychotics, to lithium, to tetrahydrocannabinol, to growth hormone, to anticonvulsants, to antidepressants, to atypical antipsychotics. Only recently has there arisen a potential “diamond in the rough” in the form of the atypical antipsychotic agent, olanzapine, which, in four randomized clinical trials, has shown superiority to placebo (two studies), chlorpromazine (one study), and aripiprazole (one study) in terms of weight gain and/or reduction in obsessional symptoms. The pharmacologic profile of olanzapine and other antipsychotic medications is discussed in light of the known pathophysiology of AN involving serotonin and dopamine systems, as well as brain-derived neurotrophic factor.
Literatur
1.
Bruch H. Eating disorders: Obesity, anorexia nervosa, and the person within. Houston: Basic Books; 1973.
2.
Steinglass JE, Eisen JL, Attia E, et al. Is anorexia nervosa a delusional disorder? An assessment of eating beliefs in anorexia nervosa. J Psychiatr Prac. 2007;13:65–71.CrossRef
3.
American Psychiatric Association. Diagnostic and statistical manual of mental disorders (DSM-IV). 4th ed. Washington: American Psychiatric Association; 1994.
4.
Maher AR, Maglione M, Bagley S, et al. Efficacy and comparative effectiveness of atypical antipsychotic medications for off-label uses in adults: a systematic review and meta-analysis. JAMA. 2011;306:1359–69.PubMedCrossRef
5.
McElroy SL, Kotwal R, Keck Jr PE, Akiskal HS. Comorbidity of bipolar and eating disorders: distinct or related disorders with shared dysregulations? J Affect Dis. 2005;86:107–27.PubMedCrossRef
6.
McElroy SL, Kotwal R, Keck Jr PE. Comorbidity of eating disorders with bipolar disorder and treatment implications. Bipolar Dis. 2006;8:686–95.CrossRef
7.
Wildes JE, Marcus MD, Fagiolini A. Prevalence and correlates of eating disorder co-morbidity in patients with bipolar disorder. Psychiatry Res. 2008;161:51–8.PubMedCrossRef
8.
Wang TS, Chou YH, Shiah IS. Combined treatment of olanzapine and mirtazapine in anorexia nervosa associated with major depression. Prog Neuro-Psychopharm Biol Psychiatry. 2006;30:306–9.CrossRef
9.
Attia E, Mayer L, Killory E. Medication response in the treatment of patients with anorexia nervosa. J Psychiatr Pract. 2001;7:157–62.PubMedCrossRef
10.
Walsh BT, Kaplan AS, Attia E, et al. Fluoxetine after weight restoration in anorexia nervosa: A randomized controlled trial. JAMA. 2006;295:2605–12.PubMedCrossRef
11.
Brewerton TD. Drug therapy for patients with eating disorders. Psychiatric Times. 2004;21:59–68.
12.
Brewerton TD. Toward a unified theory of serotonin dysregulation in eating and related disorders. Psychoneuroendocrinol. 1995;20:561–90.CrossRef
13.
Brewerton TD. Transmitter systems in the eating disorders. In: D’aemon (ed) Textbook of biological psychiatry. 2002.
14.
Brewerton TD, Steiger H. Neurotransmitter dysregulation in anorexia nervosa, bulimia nervosa and binge eating disorder. In: Brewerton TD, editor. Clinical handbook of eating disorders: An integrated approach. London: Marcel Dekker; 2004.
15.
Brewerton TD, Frampton I, Lask B. The neurobiology of anorexia nervosa. US Psychiatry. 2009;2:57–64.
16.
Kaye WH. Persistent alterations in behavior and serotonin activity after recovery from anorexia and bulimia nervosa. Ann N Y Acad Sci. 1997;817:162–78.PubMedCrossRef
17.
Kaye WH, Gwirtsman HE, George DT, Ebert MH. Altered serotonin activity in anorexia nervosa after long-term weight restoration. Arch Gen Psychiatry. 1991;48:556–62.PubMedCrossRef
18.
Kaye W, Strober M, Stein D, Gendall K. New directions in treatment research of anorexia and bulimia nervosa. Biol Psychiatry. 1999;45:1285–92.PubMedCrossRef
19.
20.
Bailer UF, Price JC, Meltzer CC, et al. Altered 5-HT(2A) receptor binding after recovery from bulimia-type anorexia nervosa: relationships to harm avoidance and drive for thinness. Neuropsychopharmacol. 2004;29:1143–55.CrossRef
21.
Bailer UF, Frank GK, Henry SE, Price JC, Meltzer CC, Mathis CA, Wagner A, Thornton L, Hoge J, Ziolko SK, Becker CR, McConaha CW, Kaye WH. Exaggerated 5-HT1A but normal 5-HT2A receptor activity in individuals ill with anorexia nervosa. Biol Psychiatry. 2007;61:1090–9.PubMedCrossRef
22.
Galusca B, Costes N, Zito NG, et al. Organic background of restrictive-type anorexia nervosa suggested by increased serotonin 1A receptor binding in right frontotemporal cortex of both lean and recovered patients: [18 F]MPPF PET scan study. Biol Psychiatry. 2008;64:1009–13.PubMedCrossRef
23.
Audenaert K, Van Laere K, Dumont F, et al. Decreased 5-HT2a receptor binding in patients with anorexia nervosa. J Nuclear Med. 2003;44:163–9.
24.
Goethals I, Vervaet M, Audenaert K, et al. Differences of cortical 5-HT2A receptor binding index with SPECT in subtypes of anorexia nervosa: relationship with personality traits? J Psychiatr Res. 2007;41:455–8.PubMedCrossRef
25.
Bailer UF, Frank GK, Henry SE, Price JC, Meltzer CC, Becker CR, Ziolko SK, Mathis CA, Wagner A, Barbarich-Marsteller NC, Putnam K, Kaye WH. Serotonin transporter binding after recovery from eating disorders. Psychopharmacol. 2007;195:315–24.CrossRef
26.
Ehrlich S, Franke L, Schott R, et al. Platelet monoamine oxidase activity in under weight and weight-recovered females with anorexia nervosa. Pharmacopsychiatry. 2008;41:226–31.PubMedCrossRef
27.
Gorwood P, Kipman A, Foulon C. The human genetics of anorexia nervosa. Eur J Pharmacol. 2003;480:163–70.PubMedCrossRef
28.
Rybakowski F, Slopien A, Dmitrzak-Weglarz M, et al. The 5-HT2A–1438 A/G and 5-HTTLPR polymorphisms and personality dimensions in adolescent anorexia nervosa: association study. Neuropsychobiology. 2006;53:33–9.PubMedCrossRef
29.
• Kiezebrink K, Mann ET, Bujac SR, Stubbins MJ, Campbell DA, Blundell JE. Evidence of complex involvement of serotonergic genes with restrictive and binge purge subtypes of anorexia nervosa. World J Biol Psychiatry. 2010;11:824–33. This recent genetic study showed a substantial and complex inter-relationship between several serotoninergic genes and AN. HTR2A was associated with both AN subtypes, while genes encoding HTR1D and HTR1B were associated with RAN and the gene encoding HTR2C was associated with BPAN. This study will help to guide future genetic research and also gives support for the use of atypical antipsychotics, such as olanzapine.PubMedCrossRef
30.
Bergen AW, van den Bree MB, Yeager M, et al. Candidate genes for anorexia nervosa in the 1p33-36 linkage region: serotonin 1D and delta opioid receptor loci exhibit significant association to anorexia nervosa. Mol Psychiatry. 2003;8:397–406.PubMedCrossRef
31.
Hu X, Giotakis O, Li T, et al. Association of the 5-HT2c gene with susceptibility and minimum body mass index in anorexia nervosa. Neuroreport. 2003;14:781–3.PubMedCrossRef
32.
Hammer C, Kapeller J, Endele M, et al. Functional variants of the serotonin receptor type 3A and B gene are associated with eating disorders. Pharmacogenet Genom. 2009;19:790–9.CrossRef
33.
Martaskova D, Slachtova L, Kemlink D, et al. Polymorphisms in serotonin-related genes in anorexia nervosa. The first study in Czech population and metaanalyses with previously performed studies. Folia Biol. 2009;55:192–7.
34.
Brown KM, Bujac SR, Mann ET, et al. Further evidence of association of OPRD1 & HTR1D polymorphisms with susceptibility to anorexia nervosa. Biol Psychiatry. 2007;61:367–73.PubMedCrossRef
35.
Hillebrand JJ, van Elburg AA, Kas MJ, van Engeland H, Adan RA. Olanzapine reduces physical activity in rats exposed to activity-based anorexia: possible implications for treatment of anorexia nervosa? Biol Psychiatry. 2005;58:651–7.PubMedCrossRef
36.
Verhagen LA, Luijendijk MC, Hillebrand JJ, Adan RA. Dopamine antagonism inhibits anorectic behavior in an animal model for anorexia nervosa. Eur Neuropsychopharmacol. 2009;19:153–60.PubMedCrossRef
37.
Wagner A, Aizenstein H, Venkatraman VK, et al. Altered reward processing in women recovered from anorexia nervosa. Am J Psychiatry. 2007;164:1842–9.PubMedCrossRef
38.
Bachner-Melman R, Lerer E, Zohar AH, et al. Anorexia nervosa, perfectionism, and dopamine D4 receptor (DRD4). Am J Med Genetics. 2007;144B:748–56.CrossRef
39.
Frank GK, Bailer UF, Henry SE, et al. Increased dopamine D2/D3 receptor binding after recovery from anorexia nervosa measured by positron emission tomography and [11c]raclopride. Biol Psychiatry. 2005;58:908–12.PubMedCrossRef
40.
Frieling H, Romer KD, Scholz S, et al. Epigenetic dysregulation of dopaminergic genes in eating disorders. Int J Eat Disord. 2010;43:577–83.PubMedCrossRef
41.
• Brandys MK, Kas MJ, van Elburg AA. A meta-analysis of circulating BDNF concentrations in anorexia nervosa. World J Biol Psychiatry. 2011;12:444–54. This study suggests that BDNF is not only an important indicator of illness and recovery but may also be a target for drug action in the treatment of AN. It is already known that atypical antipsychotics, especially olanzapine, increase BDNF levels..PubMedCrossRef
42.
Ehrlich S, Salbach-Andrae H, Eckart S, et al. Serum brain-derived neurotrophic factor and peripheral indicators of the serotonin system in underweight and weight-recovered adolescent girls and women with anorexia nervosa. J Psych Neurosci. 2009;34:323–9.
43.
Mercader JM, Fernandez-Aranda F, Gratacos M, et al. Blood levels of brain-derived neurotrophic factor correlate with several psychopathological symptoms in anorexia nervosa patients. Neuropsychobiology. 2007;56:185–90.PubMedCrossRef
44.
Monteleone P, Maj M. Genetic susceptibility to eating disorders: associated polymorphisms and pharmacogenetic suggestions. Pharmacogenomics. 2008;9:1487–520.PubMedCrossRef
45.
Stahl SM. Describing an atypical antipsychotic: Receptor binding and its role in pathophysiology. J Clin Psychiatry. 2003;5 Suppl 3:9–13.
46.
Rizos EN, Papadopoulou A, Laskos E, et al. Reduced serum BDNF levels in patients with chronic schizophrenic disorder in relapse, who were treated with typical or atypical antipsychotics. World J Biol Psychiatry. 2010;11:251–5.PubMedCrossRef
47.
Brambilla F, Garcia CS, Fassino S, et al. Olanzapine therapy in anorexia nervosa: psychological effects. Int Clin Psychopharmacol. 2007;22:197–204.PubMedCrossRef
48.
•• Bissada H, Tasca GA, Barber AM, Bradwejn J. Olanzapine in the treatment of low body weight and obsessive thinking in women with anorexia nervosa: a randomized, double-blind, placebo-controlled trial. Am J Psychiatry. 2008;165:1281–8. This is a very important randomized, placebo-controlled study that demonstrated olanzapine’s ability to promote faster weight gain and alleviate obsessive symptoms in adult patients with AN who were receiving concurrent day treatment.PubMedCrossRef
49.
•• Attia E, Kaplan AS, Walsh BT, et al. Olanzapine versus placebo for out-patients with anorexia nervosa. Psychol Med. 2011;41:2177–82. This is a recent breakthrough study which showed that olanzapine significantly facilitates weight recovery in adult outpatients with AN in comparison to placebo. This was despite the absence of any adjunctive psychotherapy or behavior therapy during the trial.PubMedCrossRef
50.
Mondraty N, Birmingham CL, Touyz S, et al. Randomized controlled trial of olanzapine in the treatment of cognitions in anorexia nervosa. Australas Psychiatry. 2005;13:72–5.PubMed
51.
Attia E, Kaplan AS, Schroeder L, Federici A. Atypical antipsychotic medication for patients with anorexia nervosa. Presented at the Annual Meeting of the Eating Disorders Research Society, Toronto, Canada, 2005.
52.
Vandereycken W, Pierloot R. Pimozide combined with behavior therapy in the short-term treatment of anorexia nervosa. A double-blind placebo-controlled cross-over study. Acta Psychiatr Scand. 1982;66:445–50.PubMedCrossRef
53.
Vandereycken W. Neuroleptics in the short-term treatment of anorexia nervosa. A double-blind placebo-controlled study with sulpiride. Br J Psychiatry. 1984;144:288–92.PubMedCrossRef
54.
• Hagman J, Gralla J, Sigel E, et al. A double-blind, placebo-controlled study of risperidone for the treatment of adolescents and young adults with anorexia nervosa: a pilot study. J Am Acad Child Adol Psych. 2011;50:915–24. This is the only randomized, placebo-controlled study that has examined the role of risperidone in the treatment of AN—in this case, adolescent inpatients being treated in a specialized eating disorder service. Although there was no difference in weight gain, those receiving risperidone demonstrated significant improvements in interpersonal distrust compared with placebo.CrossRef
55.
• Kafantaris V, Leigh E, Hertz S, et al. A placebo-controlled pilot study of adjunctive olanzapine for adolescents with anorexia nervosa. J Child Adol Psychopharmacol. 2011;21:207–12. This recent randomized, placebo-controlled study examined the role of olanzapine in a group of adolescents being treated in a specialty eating disorder service. There was no statistically significant benefit of olanzapine for weight or psychological symptoms. Again, we see that olanzapine seems to primarily benefit individuals who are not receiving concurrent intensive treatment.CrossRef
Metadaten
Titel
Antipsychotic Agents in the Treatment of Anorexia Nervosa: Neuropsychopharmacologic Rationale and Evidence from Controlled Trials
verfasst von
Timothy D. Brewerton
Publikationsdatum
01.08.2012
Verlag
Current Science Inc.
Erschienen in
Current Psychiatry Reports / Ausgabe 4/2012
Print ISSN: 1523-3812
Elektronische ISSN: 1535-1645
DOI
https://doi.org/10.1007/s11920-012-0287-6

Weitere Artikel der Ausgabe 4/2012

Current Psychiatry Reports 4/2012 Zur Ausgabe

Geriatric Disorders (DC Steffens, Section Editor)

Depression and Cognitive Impairment in Older Adults

Eating Disorders (E Attia, Section Editor)

Epidemiology of Eating Disorders: Incidence, Prevalence and Mortality Rates

Psychiatry in Primary Care (BN Gaynes, Section Editor)

Does Screening for Depression in Primary Care Improve Outcome?

Psychiatry in Primary Care (BN Gaynes, Section Editor)

Addressing Suicidality in Primary Care Settings

Psychiatry in Primary Care (BN Gaynes, Section Editor)

Clinically Significant Psychotropic Drug-Drug Interactions in the Primary Care Setting

Eating Disorders (E Attia, Section Editor)

What can Cognitive Neuroscience Teach us about Anorexia Nervosa?

Neu im Fachgebiet Psychiatrie

Demenzkranke durch Antipsychotika vielfach gefährdet

23.04.2024 Demenz Nachrichten

Wenn Demenzkranke aufgrund von Symptomen wie Agitation oder Aggressivität mit Antipsychotika behandelt werden, sind damit offenbar noch mehr Risiken verbunden als bislang angenommen.

Weniger postpartale Depressionen nach Esketamin-Einmalgabe

23.04.2024 Depression antepartal oder postpartal Nachrichten

Bislang gibt es kein Medikament zur Prävention von Wochenbettdepressionen. Das Injektionsanästhetikum Esketamin könnte womöglich diese Lücke füllen.

„Psychotherapie ist auch bei sehr alten Menschen hochwirksam!“

22.04.2024 DGIM 2024 Kongressbericht

Die Kombination aus Medikamenten und Psychotherapie gilt als effektivster Ansatz bei Depressionen. Das ist bei betagten Menschen nicht anders, trotz Besonderheiten.

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein

22.04.2024 DGIM 2024 Nachrichten

Um Menschen nach der Flucht aus einem Krisengebiet bestmöglich medizinisch betreuen zu können, ist es gut zu wissen, welche Erkrankungen im jeweiligen Herkunftsland häufig sind. Dabei hilft eine Internetseite der CDC (Centers for Disease Control and Prevention).

Update Psychiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise